Abstracts tagged "Biomarkers"

Abstract Number: 2207 • 2017 ACR/ARHP Annual Meeting
Urine CTX-II, CTX-I, Osteocalcin, and Radiographic Severity of Multiple OA Knee Joints: Does CTX-II Originate from Bone or Cartilage?
Asger R. Bihlet¹, Inger Byrjalsen², Anne C. Bay-Jensen³, Jeppe Andersen⁴, Claus Christiansen¹, Bente J. Riis¹ and Morten Asser Karsdal³, ¹Nordic Bioscience, Clinical Development, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁴Clinical Development, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Excessive cartilage degradation is a known characteristic of osteoarthritis (OA), and several methods of quantification of cartilage degradation exist. Biomarkers such as urinary C-telopeptide…
Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting
CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Vikas Gupta¹, Shobhita Katiyar², Ankita Singh², Ramnath Misra¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁴ and Anca Askanase⁸, ¹Cohen Children's Medical Center of New York, Lake Success, NY, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Columbia University Medical Center, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Pediatrics, Columbia University Medical Center, New York, NY, ⁸Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
Dirk Holzinger¹, Carolin Pretzer², Maria Miranda-Garcia^2,3, Hans Huppertz⁴, Gerd Horneff⁵, Johannes Peter Haas⁶, Gerd Ganser⁷, Jasmin B. Kuemmerle-Deschner⁸, Michael Frosch⁹, Johannes Roth¹⁰ and Dirk Foell², ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ³Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institute, Langen, Germany, ⁴Prof Hess Children’s Hospital Bremen, Bremen, Germany, ⁵Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Pediatric Pain Centre,, Children's and Adolescents' Hospital Datteln, Datteln, Germany, ¹⁰Institute of Immunology, University of Muenster, Muenster, Germany
Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium
Biologically-Based Approach for Classifying Chronic Childhood Arthritis
Elham Rezaei¹, Daniel Hogan², Brett Trost², Anthony Kusalik², Susanne Benseler³, Gilles Boire⁴, David A. Cabral⁵, Bonnie Cameron⁶, Sarah Campillo⁷, Gaëlle Chédeville⁸, Paul Dancey⁹, Ciarán M. Duffy¹⁰, Karen N Watanabe Duffy¹¹, Janet Ellsworth¹², Simon Eng¹³, Brian M. Feldman¹⁴, John Gordon², Jaime Guzman¹⁵, Kristin Houghton¹⁶, Adam Huber¹⁷, Quaid Morris¹³, Bianca Lang¹⁸, Deborah M. Levy¹⁹, Loren Matheson²⁰, Kiem Oen²¹, Ross Petty²², Suzanne Ramsey²³, Johannes Roth²⁴, Dax Rumsey²⁵, Claire Saint-Cyr²⁶, Rayfel Schneider²⁷, Rosie Scuccimarri²⁸, Earl Silverman¹⁹, Lynn R. Spiegel²⁹, Elizabeth Stringer¹⁸, Shirley M.L. Tse³⁰, Lori Tucker³¹, Rae S.M. Yeung³² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Montreal Children's Hospital, Montreal, QC, Canada, ⁸Rheumatology, McGill University, Montreal, QC, Canada, ⁹Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹²University of Alberta, Edmonton, AB, Canada, ¹³University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, ¹⁷IWK Health Centre, Halifax, NS, Canada, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University of Saskatchewan, Ottawa, ON, Canada, ²¹University of Manitoba, Winnipeg, MB, Canada, ²²Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²³Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁴Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, ²⁵Stollery Children's Hospital, Edmonton, AB, Canada, ²⁶Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, ²⁷Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, ²⁹Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ³⁰Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³¹Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ³²Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…
Abstract Number: 57 • 2017 Pediatric Rheumatology Symposium
Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis
Nikolay Tzaribachev¹, Romiesa Hagoug², Polymnia Louka³, Joyee Islam³, Mark Hinton³, Olga Kubassova⁴ and Mikael Boesen⁵, ¹PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ²Imaging, Image Analysis Group, London, United Kingdom, ³Image Analysis Group, London, United Kingdom, ⁴Image Analysis Group, Image Analysis Group, London, England, ⁵Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiskberg, Denmark
Background/Purpose: In chronic inflammatory conditions, the need for a more objective measurement of disease activity has been identified, where dynamic contrast enhanced (DCE) MRI as…
Abstract Number: 32 • 2017 Pediatric Rheumatology Symposium
High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
Hon Yan Ng¹, Stefan Slomp², Tracy Wilson-Gerwing³, Joan Dietz⁴, Abid Lodhi⁵, Tanya Holt⁶ and Alan Rosenberg³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Pediatrics, Emergency Medicine, University of Alberta, Edmonton, AB, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Regina Qu'appelle Health Region, Regina, SK, Canada, ⁶University of Saskatchewan, Sasktoon, SK, Canada
Background/Purpose: High Mobility Group Box 1 Protein (HMGB1) is a nuclear protein that stabilizes DNA and modulates gene expression. In sepsis and in certain other…
Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Nienke M. ter Haar¹, Rianne C. Scholman¹, Wilco de Jager², Nadia Ryter³, Ariane de Ganck⁴, Dirk Foell⁵, Sytze de Roock⁶ and Bas Vastert⁷, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³BÜHLMANN Laboratories AG, Basel, Switzerland, ⁴Biogazelle NV, Zwijnaarde, Belgium, ⁵Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…
Abstract Number: 143 • 2017 Pediatric Rheumatology Symposium
Influence of Age and Sex on Collagen-Induced Arthritis
Tracy Wilson-Gerwing¹, Arash Panahifar², David M.L. Cooper² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: Age and sex differences are found in certain subsets of juvenile idiopathic arthritis (JIA). Collagen Induced Arthritis (CIA) in rodents has utility in assessing…
Abstract Number: 38 • 2016 ACR/ARHP Annual Meeting
How Does Thiol/Disulphide Homeostasis Change in Fibromyalgia Patients?
Bilge Ekinci¹, Cemile Bicer², Pervin Baran³, Sema Haliloglu⁴, Hulya Uzkeser⁵ and Ayse Carlioglu⁶, ¹Physical Medicine and Rehabilitation, Erzurum Region Training and Research Hospital, Erzurum, Turkey, ²Biochemistry, Yildirim Beyazit University Medical Faculty, Ankara, Turkey, ³Biochemistry, Ataturk Training and Research Hospital, Ankara, Turkey, ⁴Physical Medicine and Rehabilitation, Maltepe Occupational Diseases Hospital, Istanbul, Turkey, ⁵Physical Medicine and Rehabilitation, Ataturk University Medical Faculty, erzuru, Turkey, ⁶Endocrinology, Erzurum Region Training and Research Hospital, Erzurum, Turkey
Background/Purpose: Our aim was to investigate the thiol/disulphide homeostasis, which has an important role in many cellular activities such as antioxidant protection, detoxification, cell growth…
Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon², Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Ivan Arias de la Rosa¹, Pedro Segui¹, Pilar Font-Ugalde¹, Maria Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, M. Carmen Castro-Villegas³, Rocio Gonzalez-Conejero⁴, Constantino Martinez⁴, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras² and Nuria Barbarroja¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…
Abstract Number: 1865 • 2016 ACR/ARHP Annual Meeting
Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Edward Stern¹, Voon H. Ong², Aine Burns³, Robert Unwin⁴ and Christopher Denton⁵, ¹UCL Division of Medicine, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, Royal Free Hospital, London, United Kingdom, ⁴Nephrology, UCL Division of Medicine, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.